A5048135389- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- Nanowire Synthesis and Applications
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Biosimilars and Bioanalytical Methods
- Advancements in Semiconductor Devices and Circuit Design
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Hematopoietic Stem Cell Transplantation
- Ubiquitin and proteasome pathways
- Bacterial Infections and Vaccines
- Integrated Circuits and Semiconductor Failure Analysis
- HER2/EGFR in Cancer Research
- Advanced Biosensing Techniques and Applications
- Bone and Joint Diseases
- AI in cancer detection
Universitätsklinikum Würzburg
2016-2025
National Center for Tumor Diseases
2025
Comprehensive Cancer Center Erlangen
2025
University of Würzburg
2015-2021
University Medical Center
2015
Institute of Medical Microbiology and Hygiene
2013
Abstract Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show short-chain fatty acids (SCFAs) pentanoate and butyrate enhance anti-tumor cytotoxic T lymphocytes (CTLs) chimeric antigen receptor (CAR) through metabolic epigenetic reprograming. We in vitro treatment CTLs CAR with increases function mTOR as a central cellular sensor, inhibits class I histone deacetylase activity. This reprogramming results elevated production...
Abstract Immunotherapy with chimeric antigen receptor-engineered T-cells (CAR-T) is under investigation in multiple myeloma. There are reports of myeloma remission after CD19 CAR-T therapy, although hardly detectable on cells by flow cytometry (FC). We apply single molecule-sensitive direct stochastic optical reconstruction microscopy ( d STORM), and demonstrate expression a fraction (10.3–80%) 10 out 14 patients (density: 13–5,000 molecules per cell). In contrast, FC detects only 2 these...
Abstract Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product treatment sites. A key ambition CARAMBA project is provide clinical proof-of-concept for virus-free CAR gene transfer using advanced Sleeping Beauty (SB) transposon technology. SB transposition CAR-T engineering attractive due high rate stable optimized...
Summary N eisseria meningitidis ( m) is a leading cause of septicemia in childhood. m unique with respect to very quick disease progression, high vivo bacterial replication rate and its considerable mortality. circumvents major mechanisms innate immunity such as complement system phagocytosis. Neutrophil extracellular traps NETs ) are formed from neutrophils during systemic infection suggested contain invading microorganisms. Here, we investigated the interaction . Both, meningococci...
Abstract Background Carfilzomib, the second‐generation proteasome inhibitor, is still awaiting approval for treatment of multiple myeloma in Europe. Results from clinical trials have demonstrated favorable efficacy advanced disease but opened an ongoing debate on cardiac complications related to carfilzomib treatment. ‘Real‐life’ data are scarce. Methods/Patients At our institution, 22 patients were registered within European Carfilzomib Access Program with carfilzomib, dexamethasone, and a...
Multiple myeloma (MM) is incurable, so there a significant unmet need for effective therapy patients with relapsed or refractory disease. This situation has not changed despite the recent approval of anti-CD38 antibody daratumumab, one most potent agents in MM treatment. The efficiency daratumumab might be improved by combining it synergistic anti-MM agents. We therefore investigated potential histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on cells, thereby enhancing...
Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas encouraged further development myeloma. In particular, maturation (BCMA)-targeted CAR-T established very promising results heavily pre-treated Moreover, targeting other antigens (i.e., SLAMF7 CD44v6) are currently under...
Although generally not applied as first-line treatment of multiple myeloma, allogeneic hematopoietic cell transplantation (allo-SCT) can still be chosen ultimate escalation approach in high-risk patients, preferentially within the framework clinical trials. In this study, we investigated whether decreasing donor chimerism (DC) is predictive for relapse. addition, comprehensively determined impact several other disease- and treatment-related factors on outcome. One hundred fifty-five myeloma...
Published experience with carfilzomib in patients relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy safety of containing therapy regimens EMD. We retrospectively analyzed 45 RRMM treated from June 2013 September 2019. median age at start was 64 (range 40–80) years. Twenty (44%) 25 (56%) had paraosseous manifestation EMD without adjacency bone, respectively. serological overall response rate (ORR) 59%....
B-cell maturation antigen (BCMA) is the lead for CAR T-cell therapy in multiple myeloma (MM). A challenge inter- and intra-patient heterogeneity BCMA expression on MM cells downmodulation under therapeutic pressure. Accordingly, there a desire to augment sustain patients that receive BCMA-CAR therapy. We used all-trans retinoic acid (ATRA) increase efficacy of T-cells pre-clinical models. show ATRA treatment leads an transcripts by quantitative PCR protein flow cytometry cell lines primary...